Post-hoc analyses of amyloid reduction after one year of treatment with donanemab using clinical trial data: prediction of amyloid clearance and association with downstream measurements
Donanemab is an antibody designed to specifically target modified amyloid that is present only in plaques. An objective of this post hoc study was to identify baseline characteristics associated with 52-week amyloid clearance (AC) with donanemab treatment and to assess the association of AC with downstream biomar...